Positive Phase 3 Trial in hATTR Amyloidosis With Polyneuropathy

The RNAi therapeutic vutrisiran met its primary and secondary endpoints in the HELIOS-A phase 3 study of patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Medscape Medical News

Source link